Mirk kinase inhibition targets ovarian cancer ascites

Genes and Cancer

Volumn 5, Issue 5-6, 2014, Pages 201-211

  Deng, Xiaobing ^a   Hu, Jing ^a   Cunningham, Mary J ^b   Friedman, Eileen ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

Ascites; Kinase; Mirk dyrk1B; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; EHT 1610; EHT 5372; EHT 6840; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MIRK KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHOSPHOTRANSFERASE; PROTEIN KINASE B; PROTEIN P130; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; ASCITES TUMOR CELL; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; MTT ASSAY; OVARIAN CANCER CELL LINE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SPHEROID; UPREGULATION; WESTERN BLOTTING;

EID: 84907518318     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Romero I, Bast RC, Jr. Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. Endocrinology. 2012;153(4):1593-602. PMCID: 3320264.
2. Ahmed AA, Becker CM, Bast RC, Jr. The origin of ovarian cancer. BJOG. 2012;119(2):134-6.
3. Bast RC, Jr., Mills GB. Dissecting “PI3Kness”: the complexity of personalized therapy for ovarian cancer. Cancer Discov. 2012;2(1):16-8. PMCID: 3354732.
4. Correa RJM, Peart T, Valdes YR, DiMattia GE, Shepherd TG. Modulation of AKT activity is associated with reversible dormancy in ascites-derived epithelial ovarian cancer spheroids. Carcinogenesis. 2012;33(1):49-58.
5. Zhang S, Balch C, Chan MW, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008;68(11):4311-20. PMCID: 2553722.
6. Takeishi S, Matsumoto A, Onoyama I, Naka K, Hirao A, Nakayama KI. Ablation of Fbxw7 eliminates leukemiainitiating cells by preventing quiescence. Cancer Cell. 2013;23(3):347-61.
7. Leder S, Weber Y, Altafaj X, Estivill X, Joost H-G, Becker W. Cloning and characterization of dyrk1B, a novel member of the dyrk family of protein kinases. Biochem Biophys Res Com. 1999;254:474-9.
8. Zou Y, Ewton D, Deng D, Mercer S, Friedman E. Mirk/dyrk1B Kinase Destabilizes Cyclin D1 by Phosphorylation at Threonine 288. J Biol Chem. 2004;279:27790-8.
9. Jin K, Ewton D, Park S, Hu J, Friedman E. Mirk regulates the exit of colon cancer cells from quiescence. J Biological Chemistry. 2009;284(34):22916-25.
10. Litovchick L, Florens LA, Swanson SK, Washburn MP, DeCaprio JA. DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly. Genes & Development. 2011;25(8):801-13.
11. Hu J, Friedman E. Depleting Mirk Kinase Increases Cisplatin Toxicity in Ovarian Cancer Cells. Genes & Cancer. 2010;1:803-11.
12. Jin K, Park S-J, Ewton D, Friedman E. The survival kinase Mirk/dyrk1B is a downstream effector of oncogenic K-ras. Cancer Res. 2007;67:7247-55.
13. Lim S, Jin K, Friedman E. Mirk Protein Kinase Is Activated by MKK3 and Functions as a Transcriptional Activator of HNF1alpha. J Biol Chem 2002;277(28):25040-6.
14. Hu J, Nakhla H, Friedman E. Transient arrest in a quiescent state allows ovarian cancer cells to survive suboptimal growth conditions and is mediated by Mirk/dyrk1B and p130/Rb2. International Journal of Cancer. 2011;129:307-18.
15. Gao J, Yang X, Yin P, et al. The involvement of FoxO in cell survival and chemosensitivity mediated by Mirk/Dyrk1B in ovarian cancer. Int J Oncol. 2012;40(4):1203-9. PMCID: 3584584.
16. Davis SJ, Sheppard KE, Pearson RB, Campbell IG, Gorringe KL, Simpson KJ. Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer. Clinical Cancer Research. 2013;19(6):1411-21.
17. Karhu R, Mahlamaki E, Kallioniemi A. Pancreatic adenocarcinoma- genetic portrait from chromosomes to microarrays. Genes Chromosomes Cancer. 2006;45:721-30.
18. Thompson FH, Nelson MA, Trent JM, et al. Amplification of 19q13.1-q13.2 sequences in ovarian cancer : G-band, FISH, and molecular studies. Cancer Genetics and Cytogenetics. 1996;87(1):55.
19. Kuuselo R, Simon R, Karhu R, et al. 19q13 amplification is associated with high grade and stage in pancreatic cancer. Genes, Chromosomes and Cancer. 2010;49(6):569-75.
20. Deng X, Ewton DZ, Friedman E. Mirk/Dyrk1B maintains the viability of quiescent pancreatic cancer cells by decreasing ROS levels. Cancer Research. 2009;69(8):3317-24.
21. Deng X, Ewton DZ, Mercer SE, Friedman E. Mirk/dyrk1B Decreases the Nuclear Accumulation of Class II Histone Deacetylases during Skeletal Muscle Differentiation. J Biol Chem 2005;280(6):4894-905.
22. Deng X, Mercer SE, Shah S, Ewton DZ, Friedman E. The Cyclin-dependent Kinase Inhibitor p27Kip1 Is Stabilized in G0 by Mirk/dyrk1B Kinase. J Biol Chem 2004;279(21):22498-504.
23. Deng X, Ewton D, Hu J, Friedman E. Mirk Kinase is Upregulated Following Inhibition of mTOR. Carcinogenesis. 2014;in press.
24. Hu J, Deng H, Friedman E. Ovarian Cancer Cells, not Normal cells, are Damaged by Mirk/Dyrk1B kinase inhibition. Int J Cancer. 2013;132(10):2258-69.
25. Xu X, Dai H, Zhao Y, Wang Y, Qian Z, Chen X. In vitro chemosensitivity assay of ascites in epithelial ovarian cancer. Eur J Gynaecol Oncol. 2013;34(6):559-64.
26. Pan J, Zhang J, Hill A, et al. A kinome-wide siRNA screen identifies multiple roles for protein kinases in hypoxic stress adaptation, including roles for IRAK4 and GAK in protection against apoptosis in VHL-/-renal carcinoma cells, despite activation of the NF-kappaB pathway. J Biomol Screen. 2013;18(7):782-96.
27. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a doubleblind, randomised, placebo-controlled phase III trial. The Lancet. 2008;372(9637):449-56.
28. Yao JC, Shah MH, Ito T, et al. Everolimus for Advanced Pancreatic Neuroendocrine Tumors. New England Journal of Medicine. 2011;364(6):514-23.
29. Lee K, Deng X, Friedman E. Mirk Protein Kinase Is a Mitogen-activated Protein Kinase Substrate That Mediates Survival of Colon Cancer Cells. Cancer Res. 2000;60(13):3631-7.
30. van der Bilt ARM, van Scheltinga AGTT, Timmer-Bosscha H, et al. Measurement of Tumor VEGF-A Levels with 89Zr-Bevacizumab PET as an Early Biomarker for the Antiangiogenic Effect of Everolimus Treatment in an Ovarian Cancer Xenograft Model. Clinical Cancer Research. 2012;18(22):6306-14.
31. Mabuchi S, Altomare DA, Connolly DC, et al. RAD001 (Everolimus) Delays Tumor Onset and Progression in a Transgenic Mouse Model of Ovarian Cancer. Cancer Research. 2007;67(6):2408-13.
32. Aide N, Kinross K, Cullinane C, et al. 18F-FLT PET as a Surrogate Marker of Drug Efficacy During mTOR Inhibition by Everolimus in a Preclinical Cisplatin-Resistant Ovarian Tumor Model. Journal of Nuclear Medicine. 2010;51(10):1559-64.
33. Chen L, Xu B, Liu L, et al. Cadmium induction of reactive oxygen species activates the mTOR pathway, leading to neuronal cell death. Free Radic Biol Med. 2011;50(5):624-32. PMCID: 3032035.
34. Leder S, Czajkowska H, Maenz B, et al. Alternative splicing variants of the protein kinase DYRK1B exhibit distinct patterns of expression and functional properties. Biochem J. 2003;372:881-8.
35. Casagrande A-S, Bachelot F, Coutadeur S, et al. Structure activity relationship of a novel chemical class of Dyrk inhibitors. Cancer Research. 2013;73:21-65.